Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: Prostate stem cell antigen (PSCA) has been suggested as biomarker and therapeutic target for prostate cancer. Recent advances showed that PSCA is up-regulated in other cancer entities, such as bladder or pancreatic cancer. However, the clinical relevance of PSCA-expression in breast cancer patients has not yet been established and is therefore addressed by the current study.
Methods: PSCA-protein expression was assessed in 405 breast cancer patients, using immunohistochemistry (PSCA antibody MB1) and tissue microarrays.
Results: PSCA-expression was detected in 94/405 patients (23%) and correlated with unfavorable histopathological grade (p=0.011) and increased Ki67 proliferation index (p=0.006). We observed a strong positive correlation between PSCA-protein expression and HER2/neu receptor status (p<0.001). PSCA did not provide prognostic information in the analyzed cohort. Interestingly, the distribution of PSCA-expression among triple negative patients was comparable to the total population.
Conclusion: We identified a subgroup of PSCA-positive breast cancer patients, which could be amenable for a PSCA-targeted therapy. Moreover, given that we found a strong positive correlation between PSCA- and HER/neu expression, targeting PSCA may provide an alternative therapeutic option in case of trastuzumab resistance.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5589606 | PMC |
| http://dx.doi.org/10.18632/oncotarget.17523 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of rs2294008 (PSCA) Gene polymorphism in Urothelial Bladder Cancer of South Indian Population.
Asian Pac J Cancer Prev
April 2025
Department of Urology, JN Medical College, KLE Academy of Higher Education and Research (Deemed-to-be-University), JNMC Campus, Belagavi-590010, India.
Background: Urothelial Bladder cancer (UBC) is a significant health problem worldwide. Prostate stem cell antigen (PSCA) gene has been reported earlier in Genome Wide Association Study (GWAS) for the risk of UBC. It is highly expressed in urothelial bladder tumours and considered to be involved in the cell proliferation inhibition and/or cell-death induction activity.
View Article and Find Full Text PDFDeveloping cell-based therapies for pancreatic ductal adenocarcinoma.
J Clin Invest
April 2025
Centre for Tumour Biology, Barts Cancer Institute, Queen Mary University of London, London, United Kingdom.
Prostate stem cell antigen (PSCA) is highly and preferentially expressed on the surface of pancreatic ductal adenocarcinoma (PDAC) cells, raising the promise of tumor-selective cell-based immunotherapies. In this issue of the JCI, Dai et al. harness PSCA for the development of an off-the-shelf chimeric antigen receptor (CAR) invariant natural killer T (iNKT) cell-based treatment for PDAC.
View Article and Find Full Text PDFOff-the-shelf invariant NKT cells expressing anti-PSCA CAR and IL-15 promote pancreatic cancer regression in mice.
J Clin Invest
April 2025
Division of Hematology/Oncology, Department of Medicine, School of Medicine, and.
Pancreatic ductal adenocarcinoma cancer (PDAC) continues to pose a significant health burden, with a 5-year survival rate of only 10%. Prostate stem cell antigen (PSCA) is highly expressed on the surface of tumor cells of most PDAC patients, with minimum expression in most normal tissues. Here, we generated cryopreserved, off-the-shelf, allogeneic PSCA chimeric antigen receptor (CAR) invariant NKT (iNKT) cells using human peripheral blood mononuclear cells as a cell source.
View Article and Find Full Text PDFDiscovery of a novel highly specific, fully human PSCA antibody and its application as an antibody-drug conjugate in prostate cancer.
MAbs
August 2024
Center for Antibody Therapeutics, Division of Infectious Diseases, Department of Medicine, University of Pittsburgh Medical School, Pittsburgh, PA, USA.
Article Synopsis
- Prostate stem cell antigen (PSCA) is important in all stages of prostate cancer and is a potential marker for other cancers like pancreatic and renal cell carcinoma.
- Researchers developed a fully human PSCA antibody, F12, that specifically targets PSCA and has shown the ability to internalize into cancer cells.
- The antibody-drug conjugate F12-MMAE demonstrated effective and specific treatment in a mouse model of prostate cancer, highlighting its potential for further research in various solid tumors.
Potential association between PSCA rs2976395 functional variant and pancreatic cancer risk.
Int J Cancer
October 2024
Department of Biology, University of Pisa, Pisa, Italy.
Article Synopsis
- CoRSIVs are regions in the genome with consistent DNA methylation patterns across tissues but show individual differences and are influenced by nearby genetic variants.
- This study focused on investigating SNPs within CoRSIVs and their potential link to pancreatic ductal adenocarcinoma (PDAC) risk, analyzing data from over 14,000 patients and 247,000 controls.
- The research identified that the A allele of SNP rs2976395 is linked to a higher risk of PDAC in Europeans and is associated with changes in DNA methylation and overexpression of the prostate stem cell antigen gene, highlighting the need for further functional studies.